Abstract
Nucleoside triphosphates were examined as the activator for various nucleoside diphosphate reductions catalyzed by a highly purified ribonucleotide reductase obtained from Molt-4F cultured human cells. It was found that cytidine 5′-diphosphate and uridine diphosphate reductions are activated by adenosine 5′-triphosphate with apparent Ka's of 0.63 ± 0.03 (S.E.) and 1.25 ± 0.10 mm, respectively. Guanosine 5′ diphosphate reduction is activated by deoxythymidine 5′-triphosphate with an apparent Ka of 1.25 ± 0.11 µm, and adenosine 5′-diphosphate reduction is activated by guanosine 5′-triphosphate or deoxyguanosine 5′-triphosphate with an apparent Ka of 1.1 ± 0.09 or 1.1 ± 0.08 mm, respectively. In the presence of saturating amounts of their best activating nucleoside triphosphates, the Km's of various nucleoside diphosphates for this purified enzyme were studied. Double reciprocal plots of velocity against substrate concentration were found to be linear for all four substrates in the concentration range tested and yielded apparent Km's of 7 ± 0.3 µm for cytidine 5′-diphosphate, 80 ± 6.5 µm for adenosine 5′-diphosphate, 33 ± 3.1 µm for guanosine 5′-diphosphate, 50 ± 2.0 µm for uridine 5′-diphosphate. The reduction of one ribonucleoside diphosphate could be inhibited by other ribonucleoside diphosphates in a noncompetitive manner.
Footnotes
-
↵1 This work was supported by USPHS Project Grant CA-18499 and Core Grant CA-13038 from the National Cancer Institute and was accomplished at Roswell Park Memorial Institute.
-
↵2 An American Leukemia Society Scholar. To whom requests for reprints should be addressed. Present address: Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, N. C. 27514.
- Received February 12, 1979.
- Accepted September 17, 1979.
- ©1979 American Association for Cancer Research.